Last reviewed: May 2026

You are mid-sentence when it happens. The thought just leaves. Not the word. The whole thought. You’re in a meeting, or at the kitchen table, or staring at something you came into this room to do, and whatever you were thinking is simply gone. Not just today. For months now.

If you already have an ADHD diagnosis, you may be wondering whether your medication has stopped working, or whether something else is happening. If you’ve never been assessed, you might be quietly Googling “early dementia” and hoping, very much, that isn’t the answer.

For many women in their 40s, what is happening is perimenopause, and it is doing something specific to the brain that clinicians are only now beginning to fully understand.

What perimenopause actually does to the brain

Perimenopause is the transitional phase before menopause, which is formally reached once a woman has gone twelve consecutive months without a period. It most commonly starts in the mid-to-late 40s, though some women begin noticing changes as early as their late 30s. During this phase, oestrogen production becomes erratic before eventually declining, and that instability matters enormously for brain function.

Oestrogen is not simply a reproductive hormone. It plays a direct role in how the brain produces and uses dopamine: the neurotransmitter at the centre of attention, motivation, and executive function (Osianlis et al., 2025). Specifically, oestrogen boosts dopamine synthesis in key brain regions including the prefrontal cortex, increases receptor density in the striatum, inhibits serotonin breakdown, and enhances the brain’s sensitivity to dopaminergic signals (Wynchank and Kooij, 2026). When oestrogen declines, all of that neurochemical scaffolding shifts. For women without ADHD, this produces the brain fog and mood changes many associate with menopause. For women with ADHD, who already have a dopamine system that functions differently, the impact is considerably more pronounced.

The research has finally caught up

A landmark 2025 population-based study published in European Psychiatry (the first of its kind), directly compared perimenopausal symptoms in women with and without ADHD across 5,392 participants (Jakobsdóttir Smári et al., 2025). The findings were striking. More than half of women with ADHD experienced severe perimenopausal symptoms, compared to around one-third of women without ADHD. The difference was consistent across psychological, somatic, and urogenital symptom domains.

What was equally significant was the timing. Symptom burden peaked between ages 35 and 39 in women with ADHD, a full decade earlier than in women without ADHD, where peak severity occurred at 45 to 49 (Jakobsdóttir Smári et al., 2025). For many women with ADHD, the perimenopausal transition is starting earlier than the medical system typically anticipates.

A 2026 narrative review in Drugs and Aging confirmed the clinical picture: there are no randomised controlled trials examining ADHD pharmacotherapy specifically in perimenopausal women. Current management is guided by expert consensus, extrapolation from younger cohorts, and small observational data (Wynchank and Kooij, 2026). The honest translation of that finding is this: the research has been slow to catch up with what women have been describing for years.

If you already have a diagnosis

Many women with well-managed ADHD reach their 40s and notice a shift that doesn’t correspond to anything they changed. The medication that was well-calibrated begins to feel ineffective. Symptoms that were previously controlled (concentration, emotional regulation, organisation) start to re-emerge.

This is a real pharmacological phenomenon. Oestrogen amplifies the brain’s sensitivity to stimulant medications. As it declines, that amplifying effect diminishes (Wynchank and Kooij, 2026). A dose that was appropriate in your late 30s may genuinely be insufficient in your mid-40s, not because of tolerance, but because the hormonal environment supporting the medication’s effectiveness has changed.

Progesterone adds another layer of complexity. It fluctuates erratically during perimenopause and exerts an antagonistic effect on dopamine signalling, potentially reducing stimulant efficacy and contributing to the week-to-week variation many women describe (Wynchank and Kooij, 2026). Some weeks the medication works; others, it barely touches the surface. This isn’t in your head, and it isn’t a failure of effort.

If you have never been diagnosed

Perimenopause is one of the most common triggers for a first ADHD assessment in adult women. This is not coincidence.

Many women with ADHD were never identified in childhood, particularly those who presented with inattention rather than hyperactivity, or who developed compensatory strategies that kept their difficulties manageable enough to go unnoticed (NICE, 2019; ADHD Guideline Development Group, 2022). For years, those strategies may have held: the lists, the routines, the sheer cognitive effort of keeping everything afloat. When oestrogen begins to decline, the neurochemical support that was quietly buffering those strategies disappears, and what was always there becomes impossible to mask (Kooij et al., 2025).

The symptoms that prompt women to see a GP at this point are frequently attributed to perimenopause alone: brain fog, forgetfulness, difficulty concentrating, emotional volatility, anxiety, disturbed sleep. These overlap substantially with ADHD, and both conditions can co-exist (ADDA, 2026). A useful clinical distinction is timeline: if difficulty with focus, organisation, and memory has been present in some form across your whole life and has become significantly worse in midlife, ADHD is likely contributing. If the cognitive symptoms appeared suddenly alongside hot flushes and cycle changes, hormonal shifts may be the primary driver. Often, it is both.

For many women, perimenopause is the moment ADHD becomes impossible to compensate for.

The scale of the phenomenon is real. In an ADDitude survey of nearly 5,000 women with ADHD, 63% of respondents aged 45 and older said ADHD had the greatest impact on their lives during perimenopause, compared to fewer than 6% who said ADHD had the biggest impact before age 20 (ADDitude Magazine, 2025). That reversal is not accidental. It reflects what happens when oestrogen declines and the dopamine system loses one of its key supports.

What about menopausal hormone therapy?

For women experiencing moderate to severe perimenopausal symptoms, menopausal hormone therapy (MHT) is the established first-line treatment (NICE, 2024). Its relevance to women with ADHD is increasingly recognised, though the evidence base remains in its early stages.

By stabilising oestrogen levels, MHT may indirectly support dopamine function and improve the hormonal environment in which ADHD medication operates (Wynchank and Kooij, 2026). Vasomotor symptoms, sleep disruption, and mood instability, each of which independently worsens ADHD, are also addressed. Some women find that stabilising oestrogen improves their response to ADHD medication, though this is an area of emerging rather than established evidence.

Current guidance does not support MHT as a primary ADHD treatment. Decisions about MHT should be made individually, based on symptoms, medical history, and personal preference, in shared decision-making with a treating doctor (NICE, 2024). What matters is that the two conversations, ADHD management and perimenopause, are held together, not as parallel and unrelated tracks.

When to bring this to clinic

If any of the following apply, an ADHD assessment is a worthwhile and important next step: ADHD medication that seemed to stop working despite nothing else changing; worsening concentration, memory, or emotional regulation in the context of irregular cycles or perimenopausal symptoms; a lifelong sense of struggling cognitively or organisationally that has become significantly harder to manage in recent years; or a suspicion that ADHD may have been missed in childhood, now amplified by hormonal change.

Pandion Health provides specialist ADHD assessment, diagnosis, and ongoing care. The perimenopause side of the picture is best managed in partnership with your GP or specialist, who can assess your hormonal status, discuss menopausal hormone therapy if appropriate, and coordinate your broader care. This kind of collaboration between your ADHD clinician and your GP is central to how Pandion works — because for women in midlife, the two conversations are clinically inseparable.

NICE guidelines explicitly note that ADHD is under-recognised in women and that women are less likely to be referred for assessment (NICE, 2019; ADHD Guideline Development Group, 2022). That is a systemic gap worth naming. You are permitted to ask for what you need.